Sign inCreate account

Report workspace tools

NCT06973187RECRUITINGanonymous

A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Sponsor

Source record

BeOne Medicines

Phase

Source record

PHASE3

Modality

AI-normalized

small molecule

Target

AI-normalized

BGB-16673, Pirtobrutinib

Indication / condition

AI-normalized

Chronic Lymphocytic Leukemia

Intervention

Source record

BGB-16673, Pirtobrutinib

Source & freshness

Source record

NCT ID

NCT06973187

Original source

ClinicalTrials.gov

Source last updated

Jun 03, 2026

Ingested at

Jun 05, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT06973187

Title

A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Sponsor

BeOne Medicines

Status

RECRUITING

Phase

PHASE3

Condition raw

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Condition normalized

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Modality raw

small molecule

Modality normalized

small molecule

Target raw

BGB-16673, Pirtobrutinib

Target normalized

BGB-16673, Pirtobrutinib

Interventions

BGB-16673, Pirtobrutinib

Public preview

Source record

The purpose of this study is to evaluate the efficacy and safety of BGB-16673 alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had been previously treated with a covalent Bruton tyrosine kinase inhibitor (cBTKi).

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT06973187

Status

RECRUITING

Phase

PHASE3

Sponsor

BeOne Medicines

Executive brief

Investment-Ready Snapshot

The purpose of this study is to evaluate the efficacy and safety of BGB-16673 alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had been previously treated with a covalent Bruton tyrosine kinase inhibitor (cBTKi).

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJun 03, 2026
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06973187

Indication

Chronic Lymphocytic Leukemia

Modality

small molecule

Target

BGB-16673, Pirtobrutinib

Intervention

BGB-16673, Pirtobrutinib

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.